Government of the Peoples Republic of Bangladesh
Directorate General of Drug Administration (DGDA)
Aushad Bhaban, Mohakhali, Dhaka-1212

Memo No: _____ Date: 13.10.2016

New Pharma
Platinum suites
Attention: Company Two (e.g. Regulatory Affairs Manager)

Subject: REVIEW DEFICIENCY LETTER

Application Reference Number: 0093/10/2016

In response to your application number mentioned above related to the Registration/Marketing Authorization of the following product, you are requested to provide response or submit the necessary document(s) to the following deficiency(ies) in order to complete the dossier evaluation process.

Trade name	ALERVIL
Generic name(s)	PHENIRAMINE MALEATE
Strength(s) per dosage unit	75 ml
Dosage form	SYRUP

See below or the attached file(s) for the list of deficiency(ies) to be addressed.

Reviewer-3 level not satisfied with module-3

The review of the application will commence again once you submit your responses. If you have any queries as to the meaning of this letter, you should contact the undersigned immediately.

Yours faithfully

Director General,
Directorate General of Drug Administration
&
Licencing Authority (Drugs)
Government of the People's Republic of Bangladesh